Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update. - Wikidata - wikimedia - TriplyDB

Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.

Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.

http://www.wikidata.org/entity/Q37404840

about

Melanized fungi in human disease Intracellular concentrations of posaconazole in different compartments of peripheral blood.Future directions in mucormycosis research.Synthesis of a highly water-soluble derivative of amphotericin B with attenuated proinflammatory activity.Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels.Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations.Invasive aspergillosis in children with hematological malignancies.

P2860

Q24633163-357C7905-58F4-4152-8BAE-EF1363A19207 Q33962775-F8EE2AAD-6181-469A-BB73-CC8DFEC27D79 Q35672102-77DCA198-2E30-4496-918B-33006F839AD7 Q37005474-E5240546-C2DF-4490-9DD1-B188EA054D02 Q37203849-7B4401BE-32AD-45A7-A23C-0A722E2FD66E Q37335720-8CFEF20E-2593-4F02-81FB-9221A1EB1B27 Q37854719-C0C6A0F1-F2C2-464B-8491-C966F2B77209

P2860

Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.

http://www.wikidata.org/entity/Q37404840

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Posaconazole's impact on proph ...... fungal infections: an update.

@en

Posaconazole's impact on proph ...... fungal infections: an update.

@nl

type

label

Posaconazole's impact on proph ...... fungal infections: an update.

@en

Posaconazole's impact on proph ...... fungal infections: an update.

@nl

prefLabel

Posaconazole's impact on proph ...... fungal infections: an update.

@en

Posaconazole's impact on proph ...... fungal infections: an update.

@nl

P1433

Q37404840-BC82D500-C7B9-4A81-B0A9-5D917F61B700

P1476

Q37404840-24C3B8ED-8CA4-41F1-BDBA-A629F1AFE17A

P2093

Q37404840-1D67B499-99BA-4E66-A5BB-6AFEA9331879

Q37404840-F8AFF094-DC93-46A9-9EAA-34C5BF61BFF0

P2860

Q37404840-00832535-8C3A-44DF-86D1-076ED4287563

Q37404840-05974582-0E5F-458F-A092-B72B0D9FE760

Q37404840-0915865C-D461-48EB-8B7F-98633CF22AD6

Q37404840-093F6096-F936-4DAD-AE12-132FB5782FD1

Q37404840-0AA03EB0-C5A3-4DE6-A32C-5423B8A1400C

Q37404840-0BE9DB7B-9575-4B9F-8932-FCB04E7F2EB5

Q37404840-0D64C1EA-EA13-4784-BDDD-966AFF3802C1

Q37404840-0E61FD63-8632-4702-83B6-1F09DFBDBA65

Q37404840-115FC6E3-3A3E-467B-AE01-8FE1E9D3E63D

Q37404840-13242805-0AF3-4B70-807A-C4E26439FBDF

P304

Q37404840-DB1E2961-90C9-4D80-A01F-23EFDBD1E913

P31

Q37404840-E2D6205E-6C20-4BB2-8ECE-C0E5EE46F4B0

P356

Q37404840-A5F7D0ED-1F6D-460F-A39A-5E9DFCF3699E

P433

Q37404840-8298B750-8C1C-4034-AA55-0358100E23CE

P478

Q37404840-5796503E-35E1-4ECB-AE1E-056111BB2034

P50

Q37404840-76DDF6E4-047C-49AB-B512-E9BA7D6919D8

P577

Q37404840-C5369970-5AD8-4591-9B84-63719A640857

P698

Q37404840-64BE0B66-2E08-49E2-BD8C-5FF6F4EC779D

P356

14787210.7.2.165

P1433

Expert Review of Anti-infective Therapy

P1476

Posaconazole's impact on proph ...... fungal infections: an update.

@en

P2093

Richard H Drew

http://www.w3.org/2001/XMLSchema#string

Winter J Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Changes in susceptibility to posaconazole in clinical isolates of Candida albicans

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions

Aspergillosis case-fatality rate: systematic review of the literature.

Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.

Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo

Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans

Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

P304

165-181

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14787210.7.2.165

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19254165

http://www.w3.org/2001/XMLSchema#string